A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas(†)

The objective of this phase I study was to determine the maximal tolerated dose (MTD) of erlotinib in patients with recurrent malignant gliomas (MGs) or recurrent meningiomas on enzyme-inducing antiepileptic drugs (EIAEDs). Dose escalation was by a standard 3 × 3 design. The initial starting dose of...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Raizer, Jeffrey J., Abrey, Lauren E., Lassman, Andrew B., Chang, Susan M., Lamborn, Kathleen R., Kuhn, John G., Yung, W.K. Alfred, Gilbert, Mark R., Aldape, Kenneth D., Wen, Patrick Y., Fine, Howard A., Mehta, Minesh, DeAngelis, Lisa M., Lieberman, Frank, Cloughesy, Timothy F., Robins, H. Ian, Dancey, Janet, Prados, Michael D.
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2010
Assuntos:
Clinical Investigations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2940559/
https://ncbi.nlm.nih.gov/pubmed/20150371
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nop017
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados